EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-PN-03(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under Indian medical guidelines, stem cell therapy for Peripheral Neuropathy is strictly investigational and administered under active Institutional Ethics Committee (IEC) oversight.
Pathophysiology & Disease Context:
Peripheral Neuropathy results from peripheral nerve damage, commonly stemming from diabetes, chemotherapy (CIPN), autoimmune conditions, or trauma.
Biological Rationale & Paracrine Action:
Investigates the immunomodulatory and trophic paracrine potential of clinical-grade mesenchymal stem cells to support tissue homeostasis, cellular repair, and inflammatory moderation.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Target Diagnoses: Chronic distal symmetric polyneuropathy, diabetic peripheral neuropathy, or chemotherapy-induced peripheral neuropathy unresponsive to conventional pharmacotherapy.
Mandatory Pre-Procedure Diagnostics:
Mandatory Diagnostic Screen: Recent Nerve Conduction Velocity (NCV) / Electromyography (EMG) studies, HbA1c panel, ankle-brachial index (ABI) to evaluate arterial flow, and baseline renal profile.
Strict Safety Exclusion Parameters:
Active foot ulcerations with osteomyelitis, severe peripheral arterial occlusive disease requiring revascularization, active malignancy, or uncontrolled systemic infection.
Triage Protocol & Multi-Specialty Clearance:
100% remote evaluation of diagnostic files by our neurology board before any travel invitation is issued.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Sensory Perception: Gradual improvements in protective sensation, reducing severe numbness in feet and hands.
- Pain Modulation: Modest reduction in burning paresthesias and neuropathic pain scores.
- Balance & Gait: Better proprioceptive awareness leading to improved stability and lower fall risk.
- Microvascular Support: Enhanced peripheral tissue perfusion and microcirculation.
Documented Procedural Risks & Limits:
- Transient puncture site soreness, low-grade fever, or localized bruising resolving in 24–48 hours.
- Mild vasovagal or infusion-related reactions.
- No Guaranteed Reversal: Chronic axon loss and long-standing severe neuropathy may show limited or no clinical response.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Hospital Accreditation
Procedures administered exclusively within tertiary facilities accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH) and JCI.
Multidisciplinary Board
Seamless oversight by senior neurologists, vascular surgeons, endocrinologists, and physiatrists.
Ethics & Compliance
Protocols monitored under an Institutional Ethics Committee registered with the CDSCO / Department of Health Research (DHR).
Ethical Enrollment
Patients are accepted only when diagnostic data indicates realistic potential for adjunctive benefit.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Teleconsultation
One-on-one video review with the lead neurologist to discuss history, diagnostic tests, and realistic expectations.
Travel & Visa Facilitation
Priority Government of India Medical Visa (MED) and Attendant (MED-X) invitation documentation.
Dedicated Case Manager
A single multilingual liaison managing appointment schedules, hospital admission, and translation needs.
Remote Follow-Up
Scheduled virtual evaluations at Months 1, 3, 6, and 12, coordinating care summaries directly with your home physician.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Airport Transfers
Complimentary, wheelchair-accessible private vehicle pick-up and drop-off.
Accommodation
Choice of private hospital suites with dedicated attendant beds or vetted accessible partner hotels within 10 minutes of the center.
Patient Amenities
Tailored dietary planning (diabetic-safe, renal-conscious, and allergen-free meals), local SIM card setup, and 24/7 nursing availability.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 4 to 5 days comprehensive in-hospital stay.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Peripheral Neuropathy
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Long-Term Clinical Cohort on Autologous BMMNCs for Refractory Diabetic Polyneuropathy
Mao, H., Wei, W., Fu, X. L., Dong, J. J., Lyu, X. Y., Jia, T., ... & Zhao, S. (2019). Efficacy of autologous bone marrow mononuclear cell transplantation therapy in patients with refractory diabetic peripheral neuropathy. Chinese Medical Journal, 132(1), 11–16.
Mechanistic Clinical Trial on Paracrine & Immunomodulatory Actions of Stem Cells
Mao, H., Dong, J. J., Lyu, X. Y., Jia, T., & Zhao, S. (2020). Autologous Bone Marrow Mononuclear Cell Transplantation Therapy Improved Symptoms in Patients with Refractory Diabetic Sensorimotor Polyneuropathy via the Mechanisms of Paracrine and Immunomodulation: A Controlled Study. Cell Transplantation, 29, 0963689720949258.
Systematic Evidence on Stem Cell Safety & Electrophysiological Metrics in DPN
Ghaffari, M., Gholami, M., & Rezaei-Tavirani, M. et al. (2024). Human studies of the efficacy and safety of stem cells in diabetic peripheral neuropathy: A systematic review and meta-analysis. Journal of Diabetes & Metabolic Disorders, 23(2), 1205–1218.
Dual Angiogenic & Neurotrophic Mechanisms of Bone Marrow MSCs in Neuropathy
Han, J. W., Choi, D., Lee, M. Y., Huh, Y. H., & Yoon, Y. S. (2016). Bone marrow-derived mesenchymal stem cells improve diabetic neuropathy by direct modulation of both angiogenesis and myelination in peripheral nerves. Cell Transplantation, 25(2), 313–326.
Statutory Notice & Mandatory Regulatory Disclosure:
In accordance with the National Guidelines for Stem Cell Research issued by the Indian Council of Medical Research (ICMR) and directives from the National Medical Commission (NMC), stem cell therapy for Peripheral Neuropathy is classified as investigational and experimental. It is not recognized as a definitive cure or standard commercial treatment. It is administered strictly within ethics-committee-approved clinical research protocols. Patients are advised never to discontinue standard primary medical management, including diabetic glycemic control, prescribed neuropathic pain medications, or lifestyle interventions.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.